These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
598 related articles for article (PubMed ID: 34208964)
21. Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions. Detjen K; Hammerich L; Özdirik B; Demir M; Wiedenmann B; Tacke F; Jann H; Roderburg C Neuroendocrinology; 2021; 111(3):217-236. PubMed ID: 32615560 [TBL] [Abstract][Full Text] [Related]
22. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636 [TBL] [Abstract][Full Text] [Related]
23. [Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)]. Klöppel G Pathologe; 2019 May; 40(3):211-219. PubMed ID: 30969346 [TBL] [Abstract][Full Text] [Related]
24. Diagnostic role and prognostic value of tumor markers in high-grade gastro-enteropancreatic neuroendocrine neoplasms. Gao C; Fan Z; Yang J; Shi M; Li Y; Zhan H Pancreatology; 2023 Mar; 23(2):204-212. PubMed ID: 36710224 [TBL] [Abstract][Full Text] [Related]
25. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors. Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240 [TBL] [Abstract][Full Text] [Related]
26. [Pathological characteristics and survival analysis of 355 patients with gastroenteropancreatic neuroendocrine neoplasms]. Li Y; Wang YF; Tan BB; Er LM; Zhao Q; Fan LQ; Zhang ZD; Liu Y Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):426-431. PubMed ID: 32482035 [No Abstract] [Full Text] [Related]
28. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification. Xu JX; Wu DH; Ying LW; Hu HG World J Gastroenterol; 2021 Dec; 27(47):8123-8137. PubMed ID: 35068858 [TBL] [Abstract][Full Text] [Related]
31. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. Fazio N; Milione M Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009 [TBL] [Abstract][Full Text] [Related]
32. [The diagnosis and treatment of G3 neuroendocrine tumors according to the new NCCN guideline]. Liang Y; Yu XJ; Chen J Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(14):982-987. PubMed ID: 35399015 [TBL] [Abstract][Full Text] [Related]
33. Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) - Current literature review of diagnostics and therapy. What has changed in the management? Jurkiewicz K; Miciak M; Kaliszewski K Pol Przegl Chir; 2024 Mar; 96(4):58-66. PubMed ID: 39138986 [TBL] [Abstract][Full Text] [Related]
34. PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. Ali AS; Langer SW; Federspiel B; Hjortland GO; Grønbæk H; Ladekarl M; Welin S; Weber Vestermark L; Arola J; Osterlund P; Knigge U; Sørbye H; Micke P; Grimelius L; Grönberg M; Tiensuu Janson E PLoS One; 2020; 15(12):e0243900. PubMed ID: 33315908 [TBL] [Abstract][Full Text] [Related]
35. BRAF Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031 [TBL] [Abstract][Full Text] [Related]
36. Peritoneal Carcinomatosis in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Clinical Impact and Effectiveness of the Available Therapeutic Options. Merola E; Prasad V; Pascher A; Pape UF; Arsenic R; Denecke T; Fehrenbach U; Wiedenmann B; Pavel ME Neuroendocrinology; 2020; 110(6):517-524. PubMed ID: 31484182 [TBL] [Abstract][Full Text] [Related]
37. TCF-3-mediated transcription of lncRNA HNF1A-AS1 targeting oncostatin M expression inhibits epithelial-mesenchymal transition via TGFβ signaling in gastroenteropancreatic neuroendocrine neoplasms. Xue J; Bai J; Long Q; Wei Y; Pan J; Li X; Tang Q Aging (Albany NY); 2021 May; 13(10):14065-14077. PubMed ID: 34037532 [TBL] [Abstract][Full Text] [Related]
39. Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study. Zhang X; Ma L; Bao H; Zhang J; Wang Z; Gong P BMC Endocr Disord; 2014 Jul; 14():54. PubMed ID: 25001493 [TBL] [Abstract][Full Text] [Related]